January 24, 2017
â¨The London School of Economics and Political Science (LSE) and Boston Consulting Group (BCG) have partnered with leading big pharma companies to create The LSE Health Market Access Academy, which aims "to train top performers from all of the world’s leading pharma companies, giving them advanced knowledge and strategies in the field of market access".
AbbVie, AstraZeneca, Amgen, Bayer, Eli Lilly, Janssen, Merck EMD, Pfizer, Roche, Sanofi, Takeda and UCB have joined the initiative to create "what will be the first collaborative market access management development program".
The weeklong program will consist of five modules that aim to deepen participants’ market access knowledge, exploring areas such as understanding access drivers and barriers, defining an integrated evidence package, creating a receptive access environment, optimizing access and value, and managing access strategy.
The first two waves of the LSE Health Market Access Academy will take place March 27-31 and September 11-15, 2017 in London, with future international delivery dates to be announced in 2018.
LSE Health encourages applications through their website, www.LSEMarketAccess.com.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.